Radiation Oncology Journal

  • 제37권3호
  • /
  • Pages.215-223
  • /
  • 2019
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy

  • Jeong, Jae-Uk (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Nam, Taek-Keun (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Song, Ju-Young (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Yoon, Mee Sun (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Ahn, Sung-Ja (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Chung, Woong-Ki (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Cho, Ick Joon (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Kim, Yong-Hyub (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Cho, Shin Haeng (Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Jung, Seung Il (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Kwon, Dong Deuk (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School)
  • 투고 : 2019.06.18
  • 심사 : 2019.08.14
  • 발행 : 2019.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To determine prognostic significance of lymphovascular invasion (LVI) in prostate cancer patients who underwent adjuvant or salvage postoperative radiotherapy (PORT) after radical prostatectomy (RP) Materials and Methods: A total of 168 patients with prostate cancer received PORT after RP, with a follow-up of ≥12 months. Biochemical failure after PORT was defined as prostate-specific antigen (PSA) ≥0.2 ng/mL after PORT or initiation of androgen deprivation therapy (ADT) for increasing PSA levels regardless of the value. We analyzed the clinical outcomes including survivals, failure patterns, and prognostic factors affecting the outcomes. Results: In total, 120 patients (71.4%) received salvage PORT after PSA levels were >0.2 ng/mL or owing to clinical failure. The 5-year biochemical failure-free survival (BCFFS), clinical failure-free survival (CFFS), distant metastasis-free survival (DMFS), overall survival, and cause-specific survival rates were 78.3%, 94.3%, 95.0%, 95.8%, and 97.3%, respectively, during a follow-up range of 12-157 months (median: 64 months) after PORT. On multivariate analysis, PSA level of ≤1.0 ng/mL at the time of receiving PORT predicted favorable BCFFS, CFFS, and DMFS. LVI predicted worse CFFS (p = 0.004) and DMFS (p = 0.015). Concurrent and/or adjuvant ADT resulted in favorable prognosis for BCFFS (p < 0.001) and CFFS (p = 0.017). Conclusion: For patients with adverse pathologic findings, PORT should be initiated as early as possible after continence recovery after RP. Even after administering PORT, LVI was an unfavorable predictive factor, and further intensive adjuvant therapy should be considered for these patients.

키워드

참고문헌

  1. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160:299-315. https://doi.org/10.1016/S0022-5347(01)62881-7
  2. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92. https://doi.org/10.1097/00000478-199603000-00004
  3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. https://doi.org/10.1001/jama.281.17.1591
  4. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007;25:2225-9. https://doi.org/10.1200/JCO.2006.09.6495
  5. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005;366:572-8. https://doi.org/10.1016/S0140-6736(05)67101-2
  6. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35. https://doi.org/10.1001/jama.296.19.2329
  7. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30. https://doi.org/10.1200/JCO.2008.18.9563
  8. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51:417-30. https://doi.org/10.4143/crt.2019.138
  9. Park J, Suh B, Shin DW, Hong JH, Ahn H. Changing patterns of primary treatment in Korean men with prostate cancer over 10 years: a nationwide population based study. Cancer Res Treat 2016;48:899-906. https://doi.org/10.4143/crt.2015.212
  10. Chang AR, Park W. Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea. Radiat Oncol J 2017;35:25-31. https://doi.org/10.3857/roj.2016.01984
  11. Rahman S, Cosmatos H, Dave G, Williams S, Tome M. Predicting pelvic lymph node involvement in current-era prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:906-10. https://doi.org/10.1016/j.ijrobp.2010.11.053
  12. Miyake M, Tanaka N, Asakawa I, et al. The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions. Prostate Int 2019;7:47-53. https://doi.org/10.1016/j.prnil.2018.04.005
  13. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-9. https://doi.org/10.1001/jama.299.23.2760
  14. Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 2011;117:3925-32. https://doi.org/10.1002/cncr.25993
  15. Hwang WL, Tendulkar RD, Niemierko A, et al. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 2018;4:e175230. https://doi.org/10.1001/jamaoncol.2017.5230
  16. Mahal BA, Hoffman KE, Efstathiou JA, Nguyen PL. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer 2015;13:e167-72.
  17. Kalbasi A, Swisher-McClure S, Mitra N, et al. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer 2014;120:3089-96. https://doi.org/10.1002/cncr.28856
  18. Stish BJ, Pisansky TM, Harmsen WS, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 2016;34:3864-71. https://doi.org/10.1200/JCO.2016.68.3425
  19. Huang Y, Huang H, Pan XW, et al. The prognostic value of lymphovascular invasion in radical prostatectomy: a systematic review and meta-analysis. Asian J Androl 2016;18:780-5. https://doi.org/10.4103/1008-682X.156636
  20. Shariat SF, Khoddami SM, Saboorian H, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 2004;171:1122-7. https://doi.org/10.1097/01.ju.0000113249.82533.28
  21. Herman CM, Wilcox GE, Kattan MW, Scardino PT, Wheeler TM. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol 2000;24:859-63. https://doi.org/10.1097/00000478-200006000-00012
  22. McNeal JE, Yemoto CE. Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol 1996;20:1351-60. https://doi.org/10.1097/00000478-199611000-00006
  23. de la Taille A, Rubin MA, Buttyan R, et al. Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate cancer patients? Eur Urol 2000;38:79-84. https://doi.org/10.1159/000020256
  24. van den Ouden D, Kranse R, Hop WC, van der Kwast TH, Schroder FH. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol Int 1998;60:17-24. https://doi.org/10.1159/000030197
  25. Brooks JP, Albert PS, O'Connell J, McLeod DG, Poggi MM. Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy. Cancer 2006;106:1521-6. https://doi.org/10.1002/cncr.21774
  26. Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016;34:3648-54. https://doi.org/10.1200/JCO.2016.67.9647
  27. Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014;66:479-86. https://doi.org/10.1016/j.eururo.2013.11.045
  28. Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017;376:417-28. https://doi.org/10.1056/NEJMoa1607529
  29. Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016;17:747-56. https://doi.org/10.1016/S1470-2045(16)00111-X
  30. King CR. The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol 2016;121:199-203. https://doi.org/10.1016/j.radonc.2016.10.026
  31. Ghadjar P, Hayoz S, Bernhard J, et al. Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 2015;33:4158-66. https://doi.org/10.1200/JCO.2015.63.3529
  32. Cozzarini C, Fiorino C, Da Pozzo LF, et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys 2012;82:191-9. https://doi.org/10.1016/j.ijrobp.2010.09.027

피인용 문헌

  1. Prognostic impact of lymphovascular invasion in pT1‐T3 gallbladder adenocarcinoma vol.122, pp.7, 2019, https://doi.org/10.1002/jso.26160
  2. 68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial vol.39, pp.11, 2021, https://doi.org/10.1007/s00345-021-03735-0